These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12389868)

  • 1. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
    Clewell HJ; Teeguarden J; McDonald T; Sarangapani R; Lawrence G; Covington T; Gentry R; Shipp A
    Crit Rev Toxicol; 2002 Sep; 32(5):329-89. PubMed ID: 12389868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry.
    Clewell HJ; Gentry PR; Covington TR; Sarangapani R; Teeguarden JG
    Toxicol Sci; 2004 Jun; 79(2):381-93. PubMed ID: 15056818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.
    Krewski D; Withey JR; Ku LF; Andersen ME
    Environ Health Perspect; 1994 Dec; 102 Suppl 11(Suppl 11):37-50. PubMed ID: 7737040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan.
    Beaudouin R; Micallef S; Brochot C
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):103-16. PubMed ID: 20122977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative structure-pharmacokinetic relationship modelling.
    Fouchécourt MO; Béliveau M; Krishnan K
    Sci Total Environ; 2001 Jul; 274(1-3):125-35. PubMed ID: 11453289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue dosimetry, physiologically-based pharmacokinetic modeling, and cancer risk assessment.
    Andersen ME
    Cell Biol Toxicol; 1989 Dec; 5(4):405-15. PubMed ID: 2627676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches for applications of physiologically based pharmacokinetic models in risk assessment.
    Thompson CM; Sonawane B; Barton HA; DeWoskin RS; Lipscomb JC; Schlosser P; Chiu WA; Krishnan K
    J Toxicol Environ Health B Crit Rev; 2008 Aug; 11(7):519-47. PubMed ID: 18584453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically-based pharmacokinetic and toxicokinetic models in cancer risk assessment.
    Krishnan K; Johanson G
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005; 23(1):31-53. PubMed ID: 16291521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical application of kinetic data in risk assessment--an IPCS initiative.
    Meek B; Renwick A; Sonich-Mullin C;
    Toxicol Lett; 2003 Feb; 138(1-2):151-60. PubMed ID: 12559699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating human interindividual biotransformation variance in health risk assessment.
    Lipscomb JC; Kedderis GL
    Sci Total Environ; 2002 Apr; 288(1-2):13-21. PubMed ID: 12013540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trichloroethylene risk assessment using a Monte Carlo analysis of parameter uncertainty in conjunction with physiologically-based pharmacokinetic modeling.
    Cronin WJ; Oswald EJ; Shelley ML; Fisher JW; Flemming CD
    Risk Anal; 1995 Oct; 15(5):555-65. PubMed ID: 7501875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mechanistic information in risk assessment for toxic chemicals.
    Becking GC
    Toxicol Lett; 1995 May; 77(1-3):15-24. PubMed ID: 7618129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical factors in assessing risk from exposure to nasal carcinogens.
    Bogdanffy MS; Mathison BH; Kuykendall JR; Harman AE
    Mutat Res; 1997 Oct; 380(1-2):125-41. PubMed ID: 9385394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.
    el-Masri HA; Thomas RS; Benjamin SA; Yang RS
    Toxicology; 1995 Dec; 105(2-3):275-82. PubMed ID: 8571364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk.
    Clewell HJ; Andersen ME
    Toxicology; 1996 Jul; 111(1-3):315-29. PubMed ID: 8711746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.